SI
BIO icon

Symmetry Investments’s Bio-Rad Laboratories Class A BIO Stock Holding History

Symmetry Investments’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,000
Closed -$990K – 117
2022
Q2 		$990K Buy
+2,000
New +$1.04M 0.24% 68
2021
Q3 		– Sell
-1,350
Closed -$870K – 127
2021
Q2 		$870K Sell
1,350
-650
-33% -$396K 0.25% 64
2021
Q1 		$1.14M Buy
2,000
+1,000
+100% +$592K 0.28% 57
2020
Q4 		$583K Buy
+1,000
New +$570K 0.16% 56

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Symmetry Investments's BIO Position: Q3 2022 in Review

Symmetry Investments sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2022, closing a stake of 2,000 shares — an estimated $990K sold.

Symmetry Investments first reported a position in BIO in Q4 2020 and held it in 4 quarters. The position peaked at $1.14M in Q1 2021. 485 funds tracked by Wall St. Rank hold BIO as of Q3 2022.

  • Symmetry Investments reported no remaining Bio-Rad Laboratories Class A position as of Q3 2022 after selling out during the quarter.
  • Symmetry Investments sold 2,000 Bio-Rad Laboratories Class A shares in Q3 2022, an estimated $990K.
  • Symmetry Investments first reported a position in Bio-Rad Laboratories Class A in Q4 2020 and held it in 4 quarters.
  • Symmetry Investments's Bio-Rad Laboratories Class A position peaked at $1.14M in Q1 2021.
  • 485 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2022.

Based on Symmetry Investments's 13F filing for Q3 2022, filed 14 Nov 2022.